Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropsacitinib (PF-06826647) and Oral Contraceptive Interaction Study
NCT04134715Phase 1Completed
- Sponsor
- Pfizer
- Start
- Oct 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ropsacitinib in plaque psoriasis, sponsored by Pfizer. Primary endpoints: Area Under the Plasma Concentration-Time Profile From Time Zero To End of Dosing Interval of Ethinyl Estradiol, Area Under the Plasma Concentration-Time Profile From Time Zero To End of Dosing Interval of Levonorgestrel and 2 more. Started Oct 2019; status: completed.
02
Drugs
ropsacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04134715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04134715.